ROTH Capital Partners acts as Co-Lead Placement Agent
for Retrophin, Inc. in its $25M PIPE financing

For more information please contact:

Investment Banking
John Chambers
Head of Healthcare Investment Banking
(646) 358-1901
jchambers@roth.com

Michael Margolis, R.Ph.
Managing Director
(646) 358-1902
mmargolis@roth.com

Warren Dunnavant II
Vice President
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

On August 16, 2013, Retrophin, Inc. (OTCQB: RTRX) ("Retrophin" or the "Company") announced a PIPE financing which resulted in gross proceeds of approximately $25 million. The Company intends to use the aggregate net proceeds of the transaction to pursue its recently announced exclusivity agreement with a major pharmaceutical company for the right to negotiate a royalty-bearing U.S. license for a product to be developed for the treatment of Autism and Schizophrenia, as well as for the continued advancement of its pipeline.

ROTH Capital Partners, LLC acted as co-lead placement agent to Retrophin in this transaction.

In addition to the transaction highlighted above, ROTH Capital Partners, LLC acted as sole placement agent for Retrophin in its $9.1 million private placement in February 2013.

 

Client Information

Retrophin is a pharmaceutical company focused on the discovery and development of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently no viable patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and others. Retrophin's lead compound, RE-021, is scheduled to begin enrollment in a potentially pivotal Phase 2 clinical trial for FSGS during 2013. (Source: Company Press Release, 8/16/2013)

 

ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com

 
About ROTH Investment Banking Venture Finance Institutional Sales & Trading
Research Corporate Services Marketing & Conferences Press Room

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2013.